J Allergy Clin Immunol Pract:慢性鼻炎是30天内再住院哮喘和慢性阻塞性肺病患者的高风险并发症

2018-08-05 AlexYang MedSci原创

哮喘和慢性阻塞性肺病(COPD)患者的早期在入院,即最后一次出院后30天内再住院,是健康护理系统的主要经济负担。上述在入院时间的测量与并发症慢性鼻炎(CR)之间的相关性并没有详细的调查,尽管CR和哮喘以及COPD之间具有明显的相关性。最近,有研究人员调查了CR与哮喘或者COPD相关的早期再入院概率之间的相关性。研究共包括了4754名哮喘患者和2176名COPD患者。哮喘患者的跟踪调查的时间(+四分

哮喘和慢性阻塞性肺病(COPD)患者的早期在入院,即最后一次出院后30天内再住院,是健康护理系统的主要经济负担。上述在入院时间的测量与并发症慢性鼻炎(CR)之间的相关性并没有详细的调查,尽管CR和哮喘以及COPD之间具有明显的相关性。最近,有研究人员调查了CR与哮喘或者COPD相关的早期再入院概率之间的相关性。

研究共包括了4754名哮喘患者和2176名COPD患者。哮喘患者的跟踪调查的时间(+四分位数范围)均值为980(+760)天,COPD为553(+827)天。与非鼻炎患者相比,30天内哮喘或者COPD相关的再入院率风险比(HR)在AR患者(分别为HR=4.4 (3.9, 5.0) 和2.4 (1.7, 3.2))以及NAR患者(分别为HR=3.7 (2.9, 4.9) 和2.6 (1.8, 3.7))显著更高。对哮喘患者来讲,AR和NAR与所有其他的共存症相比具有更高的HRs。对COPD患者来讲,AR和NAR具有与肥胖和高血压相似的HRs。

最后,研究人员指出,并发症CR与30天内哮喘和COPD相关再入院显著相关。这些发现对指导健康护理专家关注上呼吸道和下呼吸道疾病患者出院后护理是非常有用的,进一步可以减少哮喘或者COPD患者的早期再入院率。

原始出处:

Singh U, Wangia-Anderson V, Bernstein JA et al. Chronic Rhinitis Is A High-Risk Comorbidity For 30-Day Re-Admission Of Patients With Asthma And Chronic Obstructive Pulmonary Disease. J Allergy Clin Immunol Pract. 24 July 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977801, encodeId=315f19e7801f6, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Nov 23 01:49:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671893, encodeId=419a16e18932d, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Tue May 14 20:49:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862077, encodeId=7a9a18620e78d, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Dec 23 14:49:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696838, encodeId=493e169683875, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 07 14:49:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758016, encodeId=070c1e5801637, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Oct 27 09:49:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329138, encodeId=dec71329138e0, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509841, encodeId=df341509841f8, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336623, encodeId=bcb8336623c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Aug 05 11:59:38 CST 2018, time=2018-08-05, status=1, ipAttribution=)]
    2018-11-23 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1977801, encodeId=315f19e7801f6, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Nov 23 01:49:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671893, encodeId=419a16e18932d, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Tue May 14 20:49:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862077, encodeId=7a9a18620e78d, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Dec 23 14:49:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696838, encodeId=493e169683875, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 07 14:49:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758016, encodeId=070c1e5801637, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Oct 27 09:49:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329138, encodeId=dec71329138e0, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509841, encodeId=df341509841f8, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336623, encodeId=bcb8336623c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Aug 05 11:59:38 CST 2018, time=2018-08-05, status=1, ipAttribution=)]
    2019-05-14 amy0559
  3. [GetPortalCommentsPageByObjectIdResponse(id=1977801, encodeId=315f19e7801f6, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Nov 23 01:49:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671893, encodeId=419a16e18932d, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Tue May 14 20:49:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862077, encodeId=7a9a18620e78d, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Dec 23 14:49:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696838, encodeId=493e169683875, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 07 14:49:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758016, encodeId=070c1e5801637, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Oct 27 09:49:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329138, encodeId=dec71329138e0, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509841, encodeId=df341509841f8, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336623, encodeId=bcb8336623c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Aug 05 11:59:38 CST 2018, time=2018-08-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1977801, encodeId=315f19e7801f6, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Nov 23 01:49:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671893, encodeId=419a16e18932d, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Tue May 14 20:49:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862077, encodeId=7a9a18620e78d, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Dec 23 14:49:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696838, encodeId=493e169683875, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 07 14:49:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758016, encodeId=070c1e5801637, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Oct 27 09:49:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329138, encodeId=dec71329138e0, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509841, encodeId=df341509841f8, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336623, encodeId=bcb8336623c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Aug 05 11:59:38 CST 2018, time=2018-08-05, status=1, ipAttribution=)]
    2018-10-07 tomyang96
  5. [GetPortalCommentsPageByObjectIdResponse(id=1977801, encodeId=315f19e7801f6, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Nov 23 01:49:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671893, encodeId=419a16e18932d, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Tue May 14 20:49:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862077, encodeId=7a9a18620e78d, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Dec 23 14:49:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696838, encodeId=493e169683875, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 07 14:49:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758016, encodeId=070c1e5801637, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Oct 27 09:49:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329138, encodeId=dec71329138e0, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509841, encodeId=df341509841f8, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336623, encodeId=bcb8336623c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Aug 05 11:59:38 CST 2018, time=2018-08-05, status=1, ipAttribution=)]
    2018-10-27 丁鹏鹏
  6. [GetPortalCommentsPageByObjectIdResponse(id=1977801, encodeId=315f19e7801f6, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Nov 23 01:49:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671893, encodeId=419a16e18932d, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Tue May 14 20:49:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862077, encodeId=7a9a18620e78d, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Dec 23 14:49:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696838, encodeId=493e169683875, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 07 14:49:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758016, encodeId=070c1e5801637, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Oct 27 09:49:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329138, encodeId=dec71329138e0, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509841, encodeId=df341509841f8, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336623, encodeId=bcb8336623c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Aug 05 11:59:38 CST 2018, time=2018-08-05, status=1, ipAttribution=)]
    2018-08-07 膀胱癌
  7. [GetPortalCommentsPageByObjectIdResponse(id=1977801, encodeId=315f19e7801f6, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Nov 23 01:49:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671893, encodeId=419a16e18932d, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Tue May 14 20:49:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862077, encodeId=7a9a18620e78d, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Dec 23 14:49:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696838, encodeId=493e169683875, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 07 14:49:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758016, encodeId=070c1e5801637, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Oct 27 09:49:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329138, encodeId=dec71329138e0, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509841, encodeId=df341509841f8, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336623, encodeId=bcb8336623c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Aug 05 11:59:38 CST 2018, time=2018-08-05, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1977801, encodeId=315f19e7801f6, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Nov 23 01:49:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671893, encodeId=419a16e18932d, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Tue May 14 20:49:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862077, encodeId=7a9a18620e78d, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sun Dec 23 14:49:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696838, encodeId=493e169683875, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 07 14:49:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758016, encodeId=070c1e5801637, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Oct 27 09:49:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329138, encodeId=dec71329138e0, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509841, encodeId=df341509841f8, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Tue Aug 07 02:49:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336623, encodeId=bcb8336623c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Aug 05 11:59:38 CST 2018, time=2018-08-05, status=1, ipAttribution=)]
    2018-08-05 医者仁心5538

    学习了

    0

相关资讯

Int Arch Allergy Immunol:患有慢性鼻炎症状成年人的局部过敏性鼻炎

局部过敏性鼻炎(LAR)仍旧保持着诊断不足的条件,可通过自然接触气源性致敏原引起的局部lgE抗体的产生来鉴定。最近,有研究人员对LAR在之前诊断为没有AR的成年病人中的患病率进行了评估。研究包括了84名具有长期过敏症状但是皮刺试验为阴性的病人,另外,这些病人的特异性lgE抗体抵抗常见的吸入性过敏原。研究人员还利用吸入性过敏原户尘螨、链格孢属和猫过敏原进行了鼻粘膜刺激测试,之后,对在过敏挑战中对鼻粘